ubmslateRN-logo-ubm

RN Mobile Menu

Search form

Topics:

Mark Fuerst

Mark Fuerst

Posts by Author

Safety results from studies of rheumatoid arthritis patients are not fully applicable to psoriasis patients, recent studies show.

Researchers have clarified the contribution of IL-12 and IL-23 in immune regulation.

©SUWITNGAOKAEW/Shutterstock.com

New methodologies for clinical trials in lupus are in development. If successful, the next decade could see the development of new targeted therapies for lupus.

osteoporosis

(CCR 2015) A number of new osteoporosis treatments are on the near horizon, drawing on a new understanding of bone biology, as described by a speaker at the Clinical Congress of Rheumatology.

(CCR2015) Nearly 100 new molecules are in development as RA treatments. This summary of a recent presentation by the ever-eloquent Ed Keystone MD gives a brief rundown of their mechanisms, progress, and potential.

rheumatoid arthritis

(CCR 2015) A new rheumatoid arthritis (RA) research center in the UK intends to revolutionize the understanding and treatment of the rheumatoid arthritis by 2020 by using systems biology to move beyond the one-molecule paradigm.

lupus

Thrombosis risk is increased in lupus, but not all patients are equal in this regard. This slide show summarizes the key points of a new systematic review on the topic that highlights risk assessment and treatment. Full text is available via hyperlinks in the captions.

lupus

Lupus is the condition that most frequently requires attention to skin problems, but it's far from the only reason for a rheumatologist's patient to see a dermatologist. In the case of lupus, however, the lesion may be a clue to prognosis.

(ACR2014) Among the educational features at the ACR conference are two boot camps on social media skills and a partly staffed booth in the Exhibit Hall for would-be tweeters and bloggers.

By clicking Accept, you agree to become a member of the UBM Medica Community.